Oral semaglutide for weight loss, reviewed

Oral semaglutide is the first GLP-1 receptor agonist available as a tablet for weight management. A new clinical guidance article in Postgraduate Medicine (Rubino et al., June 2026) synthesises the trial evidence and offers a practical framework for clinicians incorporating the oral formulation into obesity care^[1]. The review lands at a moment when the oral route is shifting from a diabetes-only option to a credible alternative to weekly injections for weight loss.

Regulatory status

The FDA approved oral semaglutide 25 mg for chronic weight management in adults with obesity or overweight in December 2025, making it available under the Wegovy brand alongside the existing subcutaneous injection. In the EU, the EMA's CHMP adopted oral semaglutide tablets in new strengths (1.5, 4, 9, and 25 mg) under the Rybelsus label^[2]. Lower-dose oral semaglutide (3, 7, and 14 mg as Rybelsus) has been authorised for type 2 diabetes since 2019 in the US and 2020 in the EU, but the obesity indication requires the higher 25 mg dose.

Why an oral GLP-1 matters

Injectable GLP-1 receptor agonists, including subcutaneous semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro), have demonstrated substantial weight loss in clinical trials. But needle aversion, injection-site reactions, and the logistics of weekly self-injection remain barriers for a subset of patients. An oral formulation that delivers comparable efficacy could broaden the eligible population and simplify long-term adherence for those who prefer a daily tablet over a weekly injection.

What the OASIS trials showed

The evidence base for oral semaglutide in obesity rests primarily on the OASIS programme. In OASIS 1, 667 adults with overweight or obesity but without diabetes were randomised to oral semaglutide 50 mg daily or placebo. At 68 weeks, the semaglutide group achieved a mean body-weight reduction of 15.1%, compared with 2.4% on placebo^[3]. More than half (54%) of semaglutide-treated participants lost at least 15% of their body weight, versus 6% on placebo.

OASIS 4 tested the lower 25 mg oral dose in 307 adults and reported mean weight loss of 13.6% over 64 weeks, with 63% of participants achieving at least 10% weight loss^[4]. A pharmacokinetic comparison found that 82.2% of participants on oral semaglutide 25 mg reached plasma exposure levels within the same range as those receiving subcutaneous semaglutide 2.4 mg weekly, with comparable nausea and vomiting profiles^[5].

Administration requirements

The oral formulation has strict dosing conditions that distinguish it from a typical tablet. Rubino et al. emphasise that the tablet must be taken first thing in the morning on an empty stomach, swallowed whole with no more than 120 mL (4 fl oz) of plain water. Patients must then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications^[1]. These requirements exist because semaglutide is a peptide that would otherwise be degraded in the stomach; the tablet uses a permeation-enhancer technology (SNAC) that only works reliably under fasting conditions with minimal water volume.

Non-adherence to these conditions reduces bioavailability and may explain some of the variability in individual responses. The guidance recommends that clinicians spend time on these instructions during the initial prescription and revisit them if the patient reports a suboptimal response.

Safety profile

The adverse-event pattern is consistent with the broader GLP-1 receptor agonist class. In OASIS 1, gastrointestinal events occurred in 80% of semaglutide-treated participants versus 46% on placebo, but were mostly mild to moderate in severity^[3]. Nausea, diarrhoea, vomiting, and constipation are the most common complaints. Dose escalation is designed to mitigate early GI intolerance: patients start at a lower dose and titrate upward over several weeks.

Dose escalation and titration

Like the injectable formulation, oral semaglutide uses a stepped dose-escalation schedule to reduce early gastrointestinal intolerance. Patients begin at a low dose and increase at monthly intervals. For the obesity indication, the target maintenance dose is 25 mg daily. Rubino et al. note that clinicians should counsel patients to expect some GI symptoms during each dose increase and that these typically diminish within the first few weeks at each new level^[1]. Premature discontinuation during escalation is a common reason patients do not reach the therapeutic dose. The guidance recommends scheduling a follow-up within the first month to address tolerability concerns before they lead to dropout.

What the guidance does not resolve

Rubino et al. are transparent about the open questions. There is no head-to-head trial directly comparing oral and subcutaneous semaglutide for the obesity indication in a randomised controlled setting; the pharmacokinetic modelling is supportive but not a substitute for that data. Long-term durability data beyond 68 weeks is limited. And the guidance does not address cost or insurance coverage, which remain significant barriers to access in many markets. For context on discontinuation patterns across the GLP-1 class more broadly, see coverage of the GLP-1 discontinuation evidence.

How oral semaglutide compares to other options

The oral route is not the only development expanding the GLP-1 landscape. Tirzepatide, the dual GIP/GLP-1 agonist, delivered 20.9% mean weight loss in SURMOUNT-1 via weekly injection. Retatrutide, a triple agonist, reported 28.3% in TRIUMPH-1. Oral semaglutide's 13.6% to 15.1% range sits below those figures, but comparisons across trials with different populations, durations, and doses are unreliable. What oral semaglutide offers is a different delivery method, not a different class of efficacy. The relevant question for each patient is which combination of efficacy, tolerability, convenience, and adherence fits their life.

Where this fits for readers

For people who are candidates for GLP-1 therapy but reluctant to use injections, the oral option removes one barrier. But the strict administration requirements introduce a different kind of adherence challenge. The choice between oral and injectable semaglutide is a clinical conversation, not a simple swap. For background on the molecule, see the semaglutide page on this site. For broader context on how the obesity pharmacotherapy landscape is evolving, the retatrutide and tirzepatide pages cover the injectable alternatives. Anyone considering this treatment should discuss it with a healthcare provider who can assess their individual situation.